Results 101 to 110 of about 44,865 (239)
From Lobectomy to Completion Thyroidectomy: A Cohort Study and Systematic Review
Clinical Endocrinology, EarlyView.ABSTRACT Introduction The suggested management of thyroid cancer has been revised in the 2015 American Thyroid Association Management Guidelines, suggesting thyroid lobectomy alone for low‐risk thyroid cancer. However, precise patient selection is essential to identify who may need completion thyroidectomy (CT), avoiding the burden of a second surgery.
Idit Tessler +7 more
wiley +1 more source
Biological therapy in the treatment of melanoma [PDF]
, 2018 Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile +8 more
core +3 more sources
Journal of Cutaneous Pathology, EarlyView.ABSTRACT Crystal‐storing histiocytosis (CSH) is a rare histopathologic phenomenon characterized by the accumulation of crystalline material within histiocytes, most often associated with lymphoplasmacytic or plasma cell neoplasms. Cutaneous involvement is uncommon and may present diagnostic challenges.
Liangli Wang +8 more
wiley +1 more source
Therapeutic Advances in Respiratory Disease, 2018 Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within ...
Arjun Khunger +2 more
doaj +1 more source
BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry. [PDF]
, 2019 Papillary thyroid cancer (PTC) is the second most commonly diagnosed malignancy in U.S. Latinas and in Colombian women. Studies in non-Latinos indicate that BRAF and TERT mutations are PTC prognostic markers.
Bohórquez, Mabel E +10 more
core
Emerging treatment options for BRAF-mutant colorectal cancer. [PDF]
, 2018 The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments.
Atreya, Chloe E +2 more
core +2 more sources
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer +11 more
wiley +1 more source
An unusual case of intertrigo in an adult caused by purely cutaneous Langerhans cell histiocytosis [PDF]
, 2016 We report a case of persistent intertrigo in an adult, eventually diagnosed as cutaneous Langerhans cell histiocytosis (LCH). It is known that LCH has a predilection for intertriginous areas, however purely cutaneous disease as in our case, is uncommon ...
Baldacchino, Godfrey +3 more
core
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]
, 2014 BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol +5 more
core +2 more sources